Last reviewed · How we verify

NCT06014866: INSIGHT-LBBA

Conduction System Pacing With INGEVITY+

Completed Last updated 23 May 2025
What this trial tests

trial testing Cardiac pacing in Bradycardia in 1,383 participants. Completed in 27 August 2024.

Timeline
13 November 2023
Primary endpoint
27 August 2024
27 August 2024

Quick facts

Lead sponsorDuke University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,383
Start date13 November 2023
Primary completion27 August 2024
Estimated completion27 August 2024
Sites8 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Duke University

Who can join

1 Day and older, any sex, with Bradycardia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is intended to evaluate the safety and effectiveness of the Boston Scientific INGEVITY+ cardiac pacing lead when implanted in the left bundle branch area (LBBA).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Performance of an active fixation stylet-driven lead in left bundle branch area pacing: Results from INSIGHT-LBBA.
    Friedman DJ, Shadrin I, Goldbarg S, Trulock KM, et al · · 2025 · cited 3× · PMID 39914662 · DOI 10.1016/j.hrthm.2025.01.041

Verify or expand the search:

Other recruiting trials for Bradycardia

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06014866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing